Navigation Links
Duke develops nano-scale drug delivery for chemotherapy
Date:11/1/2009

a drug can be dissolved in water.

The delivery system makes use of the bacterium Escherichia coli (E. coli) which has been genetically altered to produce a specific artificial polypeptide known as a chimeric polypeptide. Since E. coli are commonly used to produce proteins, it makes for a simple and reliable production plant for these specific polypeptides with high yield.

When attached to one of these chimeric polypeptides, the drug takes on characteristics that the drug alone does not possess. Most drugs do not dissolve in water, which limits their ability to be taken in by cells. But being attached to a nanoparticle makes the drug soluble.

"When these two elements are combined in a container, they spontaneously self-assemble into a water-soluble nanoparticle," Chilkoti said. "They also self-assemble consistently and reliably in a size of 50 nanometers or so that makes them ideal for cancer therapy. Since many chemotherapeutic drugs are insoluble, we believe that this new approach could work for them as well."

The latest experiments involved doxorubicin, a commonly used agent for the treatment of cancers of the blood, breast, ovaries and other organs. The researchers injected mice with tumors implanted under their skin with either the chimeric polypeptide-doxorubicin combination or doxorubicin alone.

The mice treated with doxorubicin alone had an average tumor size 25 times greater than those treated with the new combination. The average survival time for the doxorubicin-treated mice was 27 days, compared to more than 66 days for mice getting the new formulation.

The Duke researchers now plan to test the new combination on different types of cancer, as well as tumors growing within different organs. They will also try combining these chimeric polypeptides with other insoluble drugs and test their effectiveness against tumors.


'/>"/>

Contact: Richard Merritt
richard.merritt@duke.edu
919-660-8414
Duke University
Source:Eurekalert  

Page: 1 2

Related biology news :

1. GSU professor develops new method to help keep fruit, vegetables and flowers fresh
2. Epigentek Develops a New Method of Measuring Global DNA Methylation
3. Carnegie Mellon develops innovative method to detect genetic causes of complex diseases
4. HudsonAlpha investigator develops rapid response swine flu test
5. CSHL team develops mouse models of leukemia that predict response to chemotherapy
6. MIT student develops new innovations to selectively kill cancer cells
7. When acute hepatitis develops into chronic hepatitis
8. Fujitsu Develops HDD Security Technology Based on Opal SSC Standards
9. MIT develops new way to fuse cells
10. Hypertension develops early, silently, in African-American men
11. Iowa State researcher develops new treatment method for canine eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Duke develops nano-scale drug delivery for chemotherapy
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/4/2015)... (NASDAQ: AMRI ) today reported financial and operating results for ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... in EPS from royalties in the current quarter , ... are very pleased to present another strong financial quarter, with all ...
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... The University of Utah is launching a six-year, $21.5 ... materials for uses ranging from faster computers and communications devices ... Center of Excellence in Materials Research and Innovation is being ... grant from the National Science Foundation (NSF), $6.5 million for ...
... reversible adhesives; tenaciously clinging barnacles; and surfaces that rub ... topics that will be presented at the AVS 58th ... place Oct. 30 - Nov. 4, 2011, at the ... press registration to journalists; see details below. Journalists may ...
... Three leading sci-tech experts described engineering trends for ... this summer at the Directors Guild in Los ... of Sciences (NAS) Science & Entertainment Exchange to ... and scientists that engage the public in television, ...
Cached Biology News:$21.5 million for materials research at the University of Utah 2$21.5 million for materials research at the University of Utah 3Media invited: AVS 58th International Symposium and Exhibition 2Media invited: AVS 58th International Symposium and Exhibition 3Media invited: AVS 58th International Symposium and Exhibition 4Media invited: AVS 58th International Symposium and Exhibition 5IEEE-USA/NAS Hollywood Forum describes engineering trends for entertainment industry professionals 2
(Date:8/27/2015)... ... August 27, 2015 , ... Proove Biosciences, a ... the relationship of genetics and hypertension at the International Academy of Cardiology ... British Columbia, Canada. The event, which boasts an extensive overview of the latest ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... ("MO2"), an entity wholly owned by Mr. Yuen Kam, ... has acquired the outstanding shares (the "Shares") of  Excellent ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... 24 /PRNewswire-Asia-FirstCall/ --, -- Q4 FY 2009 Revenues increased 43.2% ... to $2.2 Million with diluted EPS of $0.08, -- FY ... Increased 32.4% to $7.9 Million vs. FY08 with diluted EPS ... 124.8% to $8.3 Million, -- June 30, 2009 Cash and ...
... , , , ABBOTT PARK, ... third-quarter 2009 financial results on Wednesday, Oct. 14, 2009, before the market opens. ... a live webcast of the earnings conference call at 8 a.m. Central time ... at www.abbottinvestor.com. An archived edition of the call will be available after ...
... ... completed a $25 million round of funding. Participating investors included CTTV Investments LLC, ... Lightspeed Venture Partners. , ... South San Francisco, CA (PRWEB) September 24, 2009 -- LS9, Inc., the Renewable ...
Cached Biology Technology:Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 2Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 3Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 4Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 5Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 6Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 7Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 8Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 9Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 10Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 11Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income 12LS9 Secures $25 Million in Latest Round of Funding 2LS9 Secures $25 Million in Latest Round of Funding 3
...
...
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... for insert-end amplification of large clones such ...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: